## Lekh N Dahal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1624385/publications.pdf Version: 2024-02-01



Ι έκμ Ν Πληλι

#	Article	IF	CITATIONS
1	HIF activation enhances Fcl <sup>3</sup> RIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy. Journal of Experimental and Clinical Cancer Research, 2022, 41, 131.	3.5	9
2	Worked to the bone: antibody-based conditioning as the future of transplant biology. Journal of Hematology and Oncology, 2022, 15, 65.	6.9	9
3	Old Dog, New Trick: Type I IFN–Based Treatment for Acute Myeloid Leukemia. Molecular Cancer Research, 2021, 19, 753-756.	1.5	3
4	Investigating the Role of Indoleamine 2,3-Dioxygenase in Acute Myeloid Leukemia: A Systematic Review. Frontiers in Immunology, 2021, 12, 651687.	2.2	15
5	STINGing Viral Tumors: What We Know from Head and Neck Cancers. Cancer Research, 2021, 81, 3945-3952.	0.4	8
6	Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia. Nature Communications, 2021, 12, 5395.	5.8	15
7	Recent Progress in Interferon Therapy for Myeloid Malignancies. Frontiers in Oncology, 2021, 11, 769628.	1.3	11
8	The Soluble Isoform of CTLA-4 Correlates with Interferon-α Activity in Systemic Lupus Erythematosus. Journal of Rheumatology, 2020, 47, 302-304.	1.0	4
9	Immunological Methods to Study Monoclonal Antibody Activity in Chronic Lymphocytic Leukaemia. Methods in Molecular Biology, 2019, 1881, 173-184.	0.4	1
10	Improved Multiplex Immunohistochemistry for Immune Microenvironment Evaluation of Mouse Formalin-Fixed, Paraffin-Embedded Tissues. Journal of Immunology, 2019, 202, 292-299.	0.4	39
11	<scp>UC</scp> â€1V150, a potent <scp>TLR</scp> 7 agonist capable of activating macrophages and potentiating <scp>mA</scp> bâ€mediated target cell deletion. Scandinavian Journal of Immunology, 2018, 87, e12666.	1.3	5
12	New revelations from an old receptor: Immunoregulatory functions of the inhibitory Fc gamma receptor, Fcî³RIIB (CD32B). Journal of Leukocyte Biology, 2018, 103, 1077-1088.	1.5	17
13	Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies. Cancer Cell, 2018, 33, 664-675.e4.	7.7	78
14	Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8AT Cell Effector Function. Immunity, 2018, 49, 958-970.e7.	6.6	114
15	On the Road to Immunotherapy—Prospects for Treating Head and Neck Cancers With Checkpoint Inhibitor Antibodies. Frontiers in Immunology, 2018, 9, 2182.	2.2	15
16	Hiding in Plain Sight: Soluble Immunomodulatory Receptors. Trends in Immunology, 2018, 39, 771-774.	2.9	9
17	Shaving Is an Epiphenomenon of Type I and II Anti-CD20–Mediated Phagocytosis, whereas Antigenic Modulation Limits Type I Monoclonal Antibody Efficacy. Journal of Immunology, 2018, 201, 1211-1221.	0.4	20
18	STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy. Cancer Research, 2017, 77, 3619-3631.	0.4	69

Lekh N Dahal

#	Article	IF	CITATIONS
19	The dichotomy of T helper 17 cells in cancer. Nature Reviews Immunology, 2017, 17, 592-592.	10.6	10
20	Antibody Tumor Targeting Is Enhanced by CD27 Agonists through Myeloid Recruitment. Cancer Cell, 2017, 32, 777-791.e6.	7.7	52
21	PI3Kδ inhibition elicits anti-leukemic effects through Bim-dependent apoptosis. Leukemia, 2017, 31, 1423-1433.	3.3	12
22	TLR-3/9 Agonists Synergize with Anti-ErbB2 mAb—Letter. Cancer Research, 2017, 77, 3376-3378.	0.4	4
23	Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus. Arthritis Research and Therapy, 2016, 18, 180.	1.6	24
24	Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer?. Drug Discovery Today, 2016, 21, 1330-1338.	3.2	33
25	PI3Kĺ´Inhibition Elicits Anti-Leukemic Effects through Bim-Dependent Apoptosis. Blood, 2016, 128, 3241-3241.	0.6	0
26	Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies. Blood, 2015, 125, 1901-1909.	0.6	74
27	FcÎ <sup>3</sup> R requirements leading to successful immunotherapy. Immunological Reviews, 2015, 268, 104-122.	2.8	41
28	Rehabilitation or the death penalty: Autoimmune BÂcells in the dock. European Journal of Immunology, 2015, 45, 687-691.	1.6	2
29	Antagonistic Human FcγRIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy InÂVivo. Cancer Cell, 2015, 27, 473-488.	7.7	108
30	Development and Characterization of Monoclonal Antibodies Specific for Mouse and Human FcÎ <sup>3</sup> Receptors. Journal of Immunology, 2015, 195, 5503-5516.	0.4	37
31	Targeting the alternatively spliced soluble isoform of CTLA-4: prospects for immunotherapy?. Immunotherapy, 2014, 6, 1073-1084.	1.0	21
32	Isolation, Polarization, and Expansion of CD4+ Helper T Cell Lines and Clones Using Magnetic Beads. Methods in Molecular Biology, 2014, 1134, 237-247.	0.4	1
33	Indoleamine 2,3 dioxygenase contributes to transferable tolerance in rat red blood cell inducible model of experimental autoimmune haemolytic anaemia. Clinical and Experimental Immunology, 2013, 173, 58-66.	1.1	8
34	The soluble isoform of CTLAâ€4 as a regulator of Tâ€cell responses. European Journal of Immunology, 2013, 43, 1274-1285.	1.6	96